BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $39,425.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CMO Todd Berard sold 1,577 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the transaction, the chief marketing officer now owns 104,961 shares of the company's stock, valued at $2,624,025. The trade was a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total transaction of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Trading Up 3.7 %

BLFS traded up $0.92 during trading on Monday, reaching $25.92. The company had a trading volume of 222,832 shares, compared to its average volume of 348,620. The stock has a market cap of $1.22 billion, a P/E ratio of -24.45 and a beta of 2.04. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55. The business has a 50 day simple moving average of $26.59 and a 200-day simple moving average of $25.49. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The company had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the topic of a number of research reports. HC Wainwright boosted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Benchmark reiterated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. Finally, KeyCorp increased their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $29.86.

Institutional Trading of BioLife Solutions

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. grew its position in shares of BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider's stock worth $84,097,000 after buying an additional 36,176 shares during the last quarter. Fred Alger Management LLC lifted its stake in BioLife Solutions by 1.0% during the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock valued at $41,386,000 after acquiring an additional 16,274 shares during the period. State Street Corp increased its stake in shares of BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after acquiring an additional 95,788 shares during the period. Millennium Management LLC lifted its position in BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in BioLife Solutions by 4.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock valued at $23,028,000 after purchasing an additional 40,416 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.